BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 16510444)

  • 81. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells.
    Alfano M; Mariani SA; Elia C; Pardi R; Blasi F; Poli G
    Blood; 2009 Feb; 113(8):1699-709. PubMed ID: 18941116
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Degradation of internalized αvβ5 integrin is controlled by uPAR bound uPA: effect on β1 integrin activity and α-SMA stress fiber assembly.
    Wang L; Pedroja BS; Meyers EE; Garcia AL; Twining SS; Bernstein AM
    PLoS One; 2012; 7(3):e33915. PubMed ID: 22470492
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction.
    Tarui T; Mazar AP; Cines DB; Takada Y
    J Biol Chem; 2001 Feb; 276(6):3983-90. PubMed ID: 11053440
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
    Liang OD; Chavakis T; Kanse SM; Preissner KT
    J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
    Chang AW; Kuo A; Barnathan ES; Okada SS
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.
    Mazumdar A; Adam L; Boyd D; Kumar R
    Cancer Res; 2001 Jan; 61(1):400-5. PubMed ID: 11196194
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.
    Hillig T; Engelholm LH; Ingvarsen S; Madsen DH; Gårdsvoll H; Larsen JK; Ploug M; Danø K; Kjøller L; Behrendt N
    J Biol Chem; 2008 May; 283(22):15217-23. PubMed ID: 18362146
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells.
    Gupta R; Chetty C; Bhoopathi P; Lakka S; Mohanam S; Rao JS; Dinh DE
    Int J Oncol; 2011 Mar; 38(3):733-44. PubMed ID: 21181094
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
    Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
    J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
    Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
    Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins.
    Farris SD; Hu JH; Krishnan R; Emery I; Chu T; Du L; Kremen M; Dichek HL; Gold E; Ramsey SA; Dichek DA
    J Biol Chem; 2011 Jun; 286(25):22665-77. PubMed ID: 21536666
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Urokinase-type plasminogen activator receptor (uPAR) ligation induces a raft-localized integrin signaling switch that mediates the hypermotile phenotype of fibrotic fibroblasts.
    Grove LM; Southern BD; Jin TH; White KE; Paruchuri S; Harel E; Wei Y; Rahaman SO; Gladson CL; Ding Q; Craik CS; Chapman HA; Olman MA
    J Biol Chem; 2014 May; 289(18):12791-804. PubMed ID: 24644284
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines.
    Raghu H; Lakka SS; Gondi CS; Mohanam S; Dinh DH; Gujrati M; Rao JS
    PLoS One; 2010 Aug; 5(8):e12458. PubMed ID: 20805979
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Fibulin-5 binds urokinase-type plasminogen activator and mediates urokinase-stimulated β1-integrin-dependent cell migration.
    Kapustin A; Stepanova V; Aniol N; Cines DB; Poliakov A; Yarovoi S; Lebedeva T; Wait R; Ryzhakov G; Parfyonova Y; Gursky Y; Yanagisawa H; Minashkin M; Beabealashvilli R; Vorotnikov A; Bobik A; Tkachuk V
    Biochem J; 2012 Apr; 443(2):491-503. PubMed ID: 22280367
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Epidermal growth factor receptor-mediated regulation of urokinase plasminogen activator expression and glioblastoma invasion via C-SRC/MAPK/AP-1 signaling pathways.
    Amos S; Redpath GT; Dipierro CG; Carpenter JE; Hussaini IM
    J Neuropathol Exp Neurol; 2010 Jun; 69(6):582-92. PubMed ID: 20467333
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
    Duriseti S; Goetz DH; Hostetter DR; LeBeau AM; Wei Y; Craik CS
    J Biol Chem; 2010 Aug; 285(35):26878-26888. PubMed ID: 20501655
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Post-transcriptional regulation of urokinase-type plasminogen activator receptor expression in lipopolysaccharide-induced acute lung injury.
    Bhandary YP; Velusamy T; Shetty P; Shetty RS; Idell S; Cines DB; Jain D; Bdeir K; Abraham E; Tsuruta Y; Shetty S
    Am J Respir Crit Care Med; 2009 Feb; 179(4):288-98. PubMed ID: 19029002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.